Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression.
Kerstin JohannToszka BohnFatemeh ShahnehNatascha LutherAlexander BirkeHenriette JaurichMark HelmMatthias KleinVerena K RakerTobias BoppMatthias BarzChristian BeckerPublished in: Nature communications (2021)
The acidic tumor microenvironment in melanoma drives immune evasion by up-regulating cyclic adenosine monophosphate (cAMP) in tumor-infiltrating monocytes. Here we show that the release of non-toxic concentrations of an adenylate cyclase (AC) inhibitor from poly(sarcosine)-block-poly(L-glutamic acid γ-benzyl ester) (polypept(o)id) copolymer micelles restores antitumor immunity. In combination with selective, non-therapeutic regulatory T cell depletion, AC inhibitor micelles achieve a complete remission of established B16-F10-OVA tumors. Single-cell sequencing of melanoma-infiltrating immune cells shows that AC inhibitor micelles reduce the number of anti-inflammatory myeloid cells and checkpoint receptor expression on T cells. AC inhibitor micelles thus represent an immunotherapeutic measure to counteract melanoma immune escape.
Keyphrases
- drug delivery
- drug release
- single cell
- cancer therapy
- skin cancer
- anti inflammatory
- hyaluronic acid
- dendritic cells
- induced apoptosis
- transcription factor
- acute myeloid leukemia
- rna seq
- bone marrow
- signaling pathway
- high throughput
- immune response
- cell cycle arrest
- protein kinase
- endoplasmic reticulum stress
- binding protein
- pi k akt